Lantheus Holdings, Inc. (LNTH) Income Statement Analysis

See more : Sumitomo Chemical Company, Limited (SOMMY) Income Statement Analysis – Financial Results

Complete financial analysis of Lantheus Holdings, Inc. (LNTH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lantheus Holdings, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.

You may be interested

Lantheus Holdings, Inc. (LNTH)

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Website: https://www.lantheus.com

About Lantheus Holdings, Inc.

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	1.30B	935.06M	425.21M	339.41M	347.34M	343.37M	331.38M	301.85M	293.46M	301.60M	283.67M	288.11M	356.29M
Cost of Revenue	586.89M	353.36M	237.51M	200.65M	172.53M	168.49M	169.24M	164.07M	157.94M	176.08M	206.31M	212.91M	261.08M
Gross Profit	709.54M	581.70M	187.70M	138.76M	174.81M	174.89M	162.14M	137.78M	135.52M	125.52M	77.36M	75.20M	95.22M
Gross Profit Ratio	54.73%	62.21%	44.14%	40.88%	50.33%	50.93%	48.93%	45.64%	46.18%	41.62%	27.27%	26.10%	26.72%
Research & Development	77.71M	311.68M	44.97M	32.79M	20.02M	17.07M	18.13M	12.20M	14.36M	13.67M	30.46M	40.60M	40.95M
General & Administrative	125.46M	133.58M	150.40M	69.27M	61.24M	50.17M	49.84M	38.83M	43.89M	37.31M	33.04M	32.52M	32.86M
Selling & Marketing	141.74M	100.24M	68.42M	40.90M	41.89M	43.16M	42.32M	36.54M	34.74M	35.12M	35.23M	37.44M	38.69M
SG&A	267.19M	233.83M	218.82M	110.17M	103.13M	93.33M	92.16M	75.37M	78.63M	72.43M	68.26M	69.96M	71.55M
Other Expenses	0.00	-1.70M	-7.35M	2.20M	-6.22M	2.47M	8.64M	220.00K	-89.00K	3.00K	9.25M	34.80M	205.00K
Operating Expenses	344.90M	545.51M	263.78M	142.96M	123.15M	110.40M	110.28M	87.58M	92.99M	86.10M	98.72M	110.56M	112.50M
Cost & Expenses	931.79M	898.87M	501.30M	343.61M	295.68M	278.89M	279.53M	251.65M	250.93M	262.18M	305.03M	323.47M	373.57M
Interest Income	19.64M	2.61M	45.00K	238.00K	686.00K	167.00K	18.00K	0.00	24.00K	27.00K	104.00K	252.00K	333.00K
Interest Expense	20.02M	7.19M	7.75M	9.48M	13.62M	17.41M	18.41M	26.62M	38.72M	42.29M	42.92M	42.01M	37.66M
Depreciation & Amortization	60.04M	47.93M	42.29M	24.69M	13.38M	13.86M	19.14M	18.26M	19.65M	18.25M	25.16M	27.40M	32.76M
EBITDA	491.01M	81.83M	-25.00M	22.69M	55.62M	80.81M	77.19M	73.18M	46.59M	58.17M	7.53M	26.86M	17.74M
EBITDA Ratio	37.87%	3.69%	-19.62%	-0.59%	13.08%	19.50%	18.25%	16.70%	14.47%	19.13%	4.63%	9.40%	4.50%
Operating Income	364.64M	-13.44M	-76.09M	-4.20M	32.06M	64.49M	51.85M	56.59M	42.53M	39.42M	-18.89M	-750.00K	-17.28M
Operating Income Ratio	28.13%	-1.44%	-17.89%	-1.24%	9.23%	18.78%	15.65%	18.75%	14.49%	13.07%	-6.66%	-0.26%	-4.85%
Total Other Income/Expenses	46.30M	-9.48M	-14.21M	-7.28M	-23.03M	-14.94M	-12.21M	-28.29M	-54.31M	-41.78M	-41.65M	-7.19M	-35.90M
Income Before Tax	410.94M	26.72M	-75.04M	-11.48M	28.63M	49.55M	39.64M	28.29M	-11.78M	-2.37M	-60.54M	-42.56M	-53.18M
Income Before Tax Ratio	31.70%	2.86%	-17.65%	-3.38%	8.24%	14.43%	11.96%	9.37%	-4.01%	-0.78%	-21.34%	-14.77%	-14.92%
Income Tax Expense	84.28M	-1.35M	-3.76M	1.99M	-3.04M	9.03M	-83.75M	1.53M	2.97M	1.20M	1.01M	-555.00K	84.08M
Net Income	326.66M	28.07M	-71.28M	-13.47M	31.67M	40.52M	123.39M	26.76M	-14.75M	-3.56M	-61.56M	-42.00M	-137.26M
Net Income Ratio	25.20%	3.00%	-16.76%	-3.97%	9.12%	11.80%	37.23%	8.87%	-5.02%	-1.18%	-21.70%	-14.58%	-38.52%
EPS	4.79	0.41	-1.06	-0.25	0.81	1.06	3.31	0.84	-0.60	-0.20	-3.40	-2.36	-7.61
EPS Diluted	4.65	0.40	-1.06	-0.25	0.79	1.03	3.17	0.82	-0.60	-0.20	-3.34	-2.32	-7.61
Weighted Avg Shares Out	68.27M	68.49M	67.49M	54.13M	38.99M	38.23M	37.28M	32.04M	24.44M	17.81M	18.08M	17.79M	18.03M
Weighted Avg Shares Out (Dil)	70.24M	70.67M	67.49M	54.13M	40.11M	39.50M	38.89M	32.66M	24.44M	18.08M	18.40M	18.08M	18.03M

Lantheus Acquires Global Rights to Life Molecular Imaging's Novel Therapeutic and Diagnostic Pair Targeting GRPR for Prostate and Breast Cancers

June 27, 2024globenewswire.com

Deal Further Strengthens Lantheus' Prostate Cancer Portfolio and Expands Pipeline to Include Breast Cancer Deal Further Strengthens Lantheus' Prostate Cancer Portfolio and Expands Pipeline to Include Breast Cancer

Why Lantheus Holdings (LNTH) is a Top Momentum Stock for the Long-Term

June 24, 2024zacks.com

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

New Strong Buy Stocks for June 21st

June 21, 2024zacks.com

ASYS, LAUR, ESLT, LNTH and LMAT have been added to the Zacks Rank #1 (Strong Buy) List on June 21, 2024.

Best Value Stocks to Buy for June 21st

June 21, 2024zacks.com

LAUR, ESLT and LNTH made it to the Zacks Rank #1 (Strong Buy) value stocks list on June 21, 2024.

Radiopharm Receives Strategic Investment for up to A$18 million

June 20, 2024globenewswire.com

SYDNEY, June 20, 2024 (GLOBE NEWSWIRE) -- Radiopharm Theranostics Limited (ASX:RAD) (Radiopharm or the Company), a developer of diagnostic and therapeutic radiopharmaceutical products, has entered into strategic agreements with Lantheus Holdings, Inc. (LNTH.NASDAQ), a leading radiopharmaceutical-focused company, and its affiliates...